- Home
- EDRY vs BCAB Comparison
EDRY vs BCAB Comparison
Compare EDRY & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- BCAB
- Stock Information
- Founded
- EDRY 2018
- BCAB 2007
- Country
- EDRY Greece
- BCAB United States
- Employees
- EDRY N/A
- BCAB N/A
- Industry
- EDRY Marine Transportation
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- EDRY Consumer Discretionary
- BCAB Health Care
- Exchange
- EDRY Nasdaq
- BCAB Nasdaq
- Market Cap
- EDRY 38.5M
- BCAB 32.5M
- IPO Year
- EDRY N/A
- BCAB 2020
- Fundamental
- Price
- EDRY $11.38
- BCAB $0.49
- Analyst Decision
- EDRY
- BCAB Buy
- Analyst Count
- EDRY 0
- BCAB 2
- Target Price
- EDRY N/A
- BCAB $5.00
- AVG Volume (30 Days)
- EDRY 11.1K
- BCAB 1.7M
- Earning Date
- EDRY 02-13-2025
- BCAB 11-07-2024
- Dividend Yield
- EDRY N/A
- BCAB N/A
- EPS Growth
- EDRY N/A
- BCAB N/A
- EPS
- EDRY N/A
- BCAB N/A
- Revenue
- EDRY $65,085,280.00
- BCAB $11,000,000.00
- Revenue This Year
- EDRY $34.61
- BCAB N/A
- Revenue Next Year
- EDRY $15.93
- BCAB N/A
- P/E Ratio
- EDRY N/A
- BCAB N/A
- Revenue Growth
- EDRY 39.04
- BCAB N/A
- 52 Week Low
- EDRY $10.04
- BCAB $0.45
- 52 Week High
- EDRY $24.84
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- EDRY 43.15
- BCAB 22.62
- Support Level
- EDRY $11.43
- BCAB $0.45
- Resistance Level
- EDRY $11.80
- BCAB $0.52
- Average True Range (ATR)
- EDRY 0.50
- BCAB 0.06
- MACD
- EDRY 0.21
- BCAB 0.02
- Stochastic Oscillator
- EDRY 66.22
- BCAB 18.38
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.